{"id":513065,"date":"2021-07-14T12:58:08","date_gmt":"2021-07-14T16:58:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/"},"modified":"2021-07-14T12:58:08","modified_gmt":"2021-07-14T16:58:08","slug":"portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/","title":{"rendered":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors"},"content":{"rendered":"
\n

\n Click <\/em>
\n
\n
\n here<\/u>
\n <\/em>
\n <\/a>
\n to join the case<\/em>\n <\/p>\n

\u200bLOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm<\/u><\/a> advises investors that a class action lawsuit has been filed on behalf of Orphazyme A\/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA\u2019s June 2021 initial public offering.<\/p>\n

Investors are encouraged to contact attorney Lesley F. Portnoy<\/u><\/a>,<\/u> to determine eligibility to participate in this action, by phone 310-692-8883 or email<\/u><\/a>, or click here<\/u><\/a> to join the case.<\/p>\n

It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme\u2019s arimoclomol was not an effective treatment for Inclusion Body Myositis (\u201cIBM\u201d). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral Sclerosis (\u201cALS\u201d). Orphazyme\u2019s new drug application (\u201cNDA\u201d) for arimoclomol for the treatment of Niemann-Pick disease type C (\u201cNPC\u201d) was incomplete and require\u2202 additional data to support its benefit-risk analysis. It was not likely that The FDA would approve the Orphazyme\u2019s NDA for arimoclomol. Orphazyme\u2019s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Orphazyme.<\/p>\n

Please visit our website<\/u><\/a> to review more information and submit your transaction information.<\/p>\n

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm\u2019s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com<\/u><\/a>
310-692-8883
www.portnoylaw.com<\/a>\u00a0<\/p>\n

Attorney Advertising<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Click here to join the case \u200bLOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Orphazyme A\/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA\u2019s June 2021 initial public offering. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme\u2019s arimoclomol was not an effective treatment for Inclusion Body Myositis (\u201cIBM\u201d). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral … <\/p>\n

Continue reading “Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-513065","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPortnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Click here to join the case \u200bLOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Orphazyme A\/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA\u2019s June 2021 initial public offering. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme\u2019s arimoclomol was not an effective treatment for Inclusion Body Myositis (\u201cIBM\u201d). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral … Continue reading "Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T16:58:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\\\/S Investors\",\"datePublished\":\"2021-07-14T16:58:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/\",\"name\":\"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\\\/S Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=\",\"datePublished\":\"2021-07-14T16:58:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\\\/S Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/","og_locale":"en_US","og_type":"article","og_title":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors - Market Newsdesk","og_description":"Click here to join the case \u200bLOS ANGELES, July 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Orphazyme A\/S (“Orphazyme” or “the Company”) (NASDAQ : ORPH) investors that acquired securities in connection with FTA\u2019s June 2021 initial public offering. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that Orphazyme made misleading and false statements to the market. Orphazyme\u2019s arimoclomol was not an effective treatment for Inclusion Body Myositis (\u201cIBM\u201d). Additionally, Arimoclomol was not an effective treatment for Amyotrophic Lateral … Continue reading \"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-14T16:58:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors","datePublished":"2021-07-14T16:58:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/","name":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=","datePublished":"2021-07-14T16:58:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU3NyM0Mjk3NjY5IzIxOTU1Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-orphazyme-a-s-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Portnoy Law: Lawsuit Filed On Behalf of Orphazyme A\/S Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=513065"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513065\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=513065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=513065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=513065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}